Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
260 hedge funds and large institutions have $9.15B invested in Mirati Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 94 increasing their positions, 99 reducing their positions, and 60 closing their positions.
48% more call options, than puts
Call options by funds: $129M | Put options by funds: $87.6M
5% less repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 99
8% less funds holding
Funds holding: 284 → 260 (-24)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
21% less capital invested
Capital invested by funds: $11.5B → $9.15B (-$2.37B)
33% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$139M |
| 2 |
BlackRock
New York
|
+$58M |
| 3 |
RI
RTW Investments
New York
|
+$55.2M |
| 4 |
AC
Armistice Capital
New York
|
+$52.3M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$48.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$86.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$64M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$58.8M |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$57.3M |
| 5 |
PA
Perceptive Advisors
New York
|
-$43.4M |
MRTX Hedge Fund Activity: Q1 2021 in Review
260 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2021, worth a combined $9.15B — down 21% from $11.5B a quarter earlier.
Sellers outnumbered buyers: 60 funds closed out of MRTX and 40 opened new positions — a net loss of 20 holders — while 99 trimmed existing stakes and 94 added.
The largest buyer was Franklin Resources, adding an estimated $139M. The largest seller was Sands Capital Management, exiting entirely with an estimated $86.5M sold.
- 260 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2021, down from 284 in Q4 2020.
- Funds reported $9.15B of Mirati Therapeutics, Inc. Common Stock stock for Q1 2021, down 21% quarter-over-quarter.
- 40 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2021 and 60 closed out, a net change of -20 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2021 was Franklin Resources, an estimated $139M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2021 was Sands Capital Management, an estimated $86.5M sold.
Based on aggregated 13F filings for Q1 2021.